Asparaginase-associated pancreatitis complicates 2-10% of patients treated for acute lymphoblastic leukemia, causing morbidity and discontinuation of asparaginase administration. Among acute complications, pancreatic fluid collections can be managed conservatively, but intervention is indicated when associated with persistent insulin therapy need and recurrent abdominal pain. Endoscopic treatment has become the standard approach in adult patients, with increasing favorable evidence in children. This work compares the characteristics of a pediatric oncology patient treated at our institution with reported literature experiences, showing feasibility, safety and effectiveness of endoscopic approach.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10742384 | PMC |
| http://dx.doi.org/10.46989/001c.90958 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk factors and a prediction model of severe asparaginase-associated pancreatitis in children.
Ann Hematol
December 2024
Department of Gastroenterology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, No. 1678 Dongfang Road, Shanghai, China.
We aimed to investigate whether early clinical indicators were associated with eventual disease severity, and to develop a predictive model for severe asparaginase-associated pancreatitis (AAP). Seventy-five acute lymphoblastic leukaemia (ALL) cases with AAP admitted to Shanghai Children's Medical Center from March 2013 to August 2023 were divided into non-severe (n = 44) and severe (n = 31) groups based on Atlanta diagnostic and AAP grading criteria. We compared essential information, asparaginase(ASP) dosage form, cumulative dose, clinical characteristics and laboratory tests between the groups.
View Article and Find Full Text PDFAcute pancreatitis following asparaginase treatment in pediatric acute lymphoblastic leukemia with a heterozygous c.194 + 2T>C intronic variant: a case report.
Front Pediatr
November 2024
Department of Pediatrics, Affiliated Changzhou Children's Hospital of Nantong University, Changzhou, Jiangsu, China.
Article Synopsis
- Asparaginase is crucial in treating pediatric acute lymphoblastic leukemia (ALL) but can lead to complications like asparaginase-associated pancreatitis (AAP), with genetic factors influencing this risk.
- A case study of a 4-year-old girl diagnosed with B-cell ALL revealed AAP after starting treatment, linked to a specific genetic variant associated with increased pancreatitis susceptibility.
- The patient's pancreatitis was managed effectively, and she achieved complete remission through an asparaginase-free treatment plan, highlighting the importance of genetic screening for improved patient outcomes.
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Haematologica
November 2024
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
BCL-2 protein overexpression, common in B-cell acute lymphoblastic leukemia (B-ALL), including the Philadelphia (Ph)-like subtype, mediates leukemic cell survival. We treated 24 patients with 14 days of BCL-2 inhibitor, venetoclax, 400 mg daily (dose level 1) during induction and consolidation cycles combined with the CALGB 10403 regimen in newly diagnosed adults with Ph-negative B-ALL. Median age was 31 (range: 18-53) years, 92% were Hispanic, and 12 (50%) patients had Ph-like ALL.
View Article and Find Full Text PDFEffects of asparaginase-associated pancreatitis in children with haematological tumours.
Front Oncol
October 2024
Department of Pediatric Gastroenterology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background: Asparaginase-associated pancreatitis (AAP) is a major challenge for continuing asparaginase therapy. We aimed to investigate the acute and long-term complications and survival rates related to first and second AAP episodes in Chinese children with haematological malignancies.
Methods: We retrospectively analysed clinical data of children with pancreatitis who received asparaginase chemotherapy for acute lymphoblastic leukaemia (ALL), acute mixed cell leukaemia, and non-Hodgkin's lymphoma at Shanghai Children's Medical Center from November 2013 to November 2023.
Acute Pancreatitis Caused by Pegylated (PEG)-Asparaginase Associated With Severe Hypertriglyceridemia.
Cureus
June 2024
Endocrinology, Diabetes and Metabolism, John H. Stroger, Jr. Hospital of Cook County, Chicago, USA.
Pegylated (PEG)-asparaginase is used during the induction and intensification phases of treatment for B-cell acute lymphoblastic leukemia (B-ALL). It works by depleting the external sources of asparagine, causing the death of lymphoblasts. It has several adverse effects, including pancreatitis and hypertriglyceridemia; however, the simultaneous occurrence of both is uncommon.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!